Related Experiment Video
Updated: Jan 23, 2026
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
Published on: August 18, 2023
Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth
Min Yao1,2, Wenli Sai2, Wenjie Zheng2
1Medical School of Nantong University, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Background:
Although secretory clusterin (sCLU) plays a crucial role in Hepatocellular Carcinoma (HCC) cells proliferation, Multiple Drug Resistance (MDR), metastasis and so on, its targeted effects and exact mechanism are still unknown. This review summarizes some new progress in sCLU as a molecular-targeted therapy in the treatment of HCC.
Methods:
A systematic review of the published English-language literature about sCLU and HCC has been performed using the PubMed and bibliographic databases. Some valuable studies on sCLU in HCC progression were searched for relevant articles with the keywords: HCC, diagnosis, MDR, as molecular-targeted in treatment, and so on.
Results:
The incidence of the positive rate of sCLU was significantly higher in HCC tissues as compared to the surrounding tissues at mRNA or protein level, gradually increasing with tumor-nodemetastasis staging (P<0.05). Also, the abnormal level of sCLU was related to poor differentiation degree, and considered as a useful marker for HCC diagnosis or independent prognosis for patients. Hepatic sCLU could be silenced at mRNA level by specific sCLU-shRNA or by OGX-011 to inhibit cancer cell proliferation with an increase in apoptosis, cell cycle arrest, reversal MDR, alteration of cell migration or invasion behaviors, and a decrease in GSK-3β or AKT phosphorylation in vitro, as well as significant suppression of the xenograft growth by down-regulating β-catenin, p-GSK3β, and cyclinD1 expression in vivo.
Conclusion:
Abnormal hepatic sCLU expression should not only be a new diagnostic biomarker but also a novel promising target for inhibiting HCC growth.
Insights
Secretory clusterin (sCLU) is elevated in Hepatocellular Carcinoma (HCC) and linked to poor prognosis. Targeting sCLU inhibits HCC growth, offering a new diagnostic and therapeutic strategy for this cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Secretory clusterin (sCLU) is implicated in Hepatocellular Carcinoma (HCC) progression, including proliferation, multidrug resistance (MDR), and metastasis.
- The precise mechanisms and targeted effects of sCLU in HCC remain incompletely understood.
Purpose of the Study:
- To review recent advancements in understanding sCLU as a molecular target for HCC treatment.
- To explore the diagnostic and prognostic value of sCLU in HCC.
Main Methods:
- Systematic literature review of PubMed and bibliographic databases.
- Searched for studies on sCLU in HCC progression, diagnosis, MDR, and targeted therapy.
- Keywords included: HCC, diagnosis, MDR, molecular-targeted therapy.
Main Results:
- Elevated sCLU mRNA and protein levels were observed in HCC tissues, correlating with advanced tumor stage and poor differentiation.
- sCLU serves as a potential diagnostic marker and independent prognostic factor for HCC patients.
- In vitro and in vivo studies demonstrated that silencing sCLU (e.g., using sCLU-shRNA or OGX-011) inhibits HCC cell proliferation, induces apoptosis, causes cell cycle arrest, reverses MDR, and suppresses tumor growth by modulating key signaling pathways (e.g., AKT, GSK-3β, β-catenin).
Conclusions:
- Abnormal hepatic sCLU expression is a promising diagnostic biomarker for HCC.
- Targeting sCLU represents a novel and effective therapeutic strategy for inhibiting HCC growth.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Secretory Phase
Following ovulation, the corpus luteum, a temporary endocrine structure, produces progesterone and estrogens. These hormones stimulate the growth and coiling of endometrial...
01:08Molecular Weight of Step-Growth Polymers
As the step-growth polymerization involves step-wise condensation of monomers, the molecular weight also builds up eventually. Consequently, high molecular weight polymers are obtained at the late stages of the polymerization, where 99% of monomers have been consumed.
The extent of the...
00:46Feedback Inhibition
01:17Role of ER in the Secretory Pathway
Components of the secretory pathway
About a third of proteins synthesized in the cell are sorted via the secretory route. They shuffle between different compartments in membrane-bound vesicles until they reach their final destination. The main intracellular compartments involved...
01:33Overview of Secretory Vesicles
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...